Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
about
Potentiating cancer immunotherapy using an oncolytic virusVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerEmerging role of Natural killer cells in oncolytic virotherapyOncolytic viruses as anticancer vaccinesThe in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunityImpact of tumor microenvironment on oncolytic viral therapyEnhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cellsThe combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host.Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsNK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.Pharmacologic and chemical adjuvants in tumor virotherapy.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Oncolytic virotherapySorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.Role of NK cells in immunotherapy and virotherapy of solid tumors.Immune System, Friend or Foe of Oncolytic Virotherapy?The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.Oncolytic viruses from the perspective of the immune system.Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy.VSV based virotherapy in ovarian cancer: the past, the present and …future?Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
P2860
Q24628810-AA2B3B68-F438-4309-988F-331D0BA2191AQ27021839-F4E12BF4-A36A-4933-A86E-3105C0A56223Q27025330-E83684F3-6592-4107-A6C4-4C73E9E75320Q27025600-CFAEF64C-FDAE-4CB6-9712-C80EED70F5C5Q33670728-B7B55837-41DA-4457-928D-CFD962CD259CQ33895533-2E4CB1C5-BECC-4396-8959-05258FCEA57AQ34076490-7211819E-8CA8-4C4E-9E64-C6A9C1C3FFB8Q34316241-C06A723D-ACB0-44C9-A3D3-612AB17D49F5Q34343742-5C35F598-83AA-430A-AAFA-C0ADD0F34E89Q35665220-171E4987-920F-4CF0-BE68-84CCBE43544EQ35687743-6CAB2EB9-8875-499E-8CAD-4CE0262A0F28Q36890816-01021F95-45AC-4024-BE0D-E0D815CF2604Q36937117-1CCEFBED-B676-4B45-98C1-52D629BAEBABQ37123143-0DB3FCED-BC0C-469F-9DDA-1A398CDD6C74Q37316860-C4F6F44C-261D-46EE-954B-374C0B2047D7Q37418123-936AD3C4-68A3-44C4-865F-ACCA644139B1Q37492540-BFFDF7E3-EC2C-43F0-A2DD-CE116F675885Q37564490-23F5A477-6F72-483F-9CF8-422D470331F6Q37602550-516BAFD4-B415-4897-A14C-6F8FD9C310C6Q37933439-0CF866E5-7655-4CDE-A060-449BD3FDDA65Q38025263-9E8A6DC9-948C-4E34-B175-BC46762B2C94Q38209337-FE72189F-3468-46E0-870E-BBCBC27D58B0Q38575116-9DC27B2D-0E5E-4554-BEB9-E1CD0CC47DD9Q39355854-2917F92C-7588-472C-A6DC-43E65CB5D2B0Q39399591-F2C0F3FC-5C28-4444-A2E7-E95F8D94DD3EQ39917875-0E517518-28EA-49D9-B150-BD4F26F4384CQ39974038-AB7B129F-441F-4E7F-9D3C-F4DBA1436C96Q40192795-6AE97EA3-63CE-4311-A1BB-91D407D35E02Q40725309-8F99191E-98CE-459A-9621-04D8709B584EQ41441101-85AE18BC-15EB-4E5C-B041-0F78740977C8Q52688581-B3297D13-0A5E-4134-980C-D4EAA1F8DE78Q54378300-5275DBE7-1621-42F5-8D97-14FA6DAA8CD6Q58600219-9DC3B36A-A4DF-4979-83C3-4406DE3A6BE1
P2860
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Exponential enhancement of onc ...... nflammatory responses in vivo.
@en
type
label
Exponential enhancement of onc ...... nflammatory responses in vivo.
@en
prefLabel
Exponential enhancement of onc ...... nflammatory responses in vivo.
@en
P2093
P2860
P50
P356
P1433
P1476
Exponential enhancement of onc ...... nflammatory responses in vivo.
@en
P2093
Marcia Meseck
Oliver Ebert
Savio L C Woo
P2860
P304
P356
10.1038/SJ.MT.6300343
P577
2007-12-11T00:00:00Z